var path='https://www.tickertech.net'; function heading(heading) { document.write('
'+heading+' |
'+ ''+ ' |
'); } function hiLite(imgDocID,imgObjName) { document.images[imgDocID].src = eval(imgObjName + ".src"); } function showStatus(toshow) { window.status = toshow; } function checkChoose() { if (document.choose.ticker.value == "") { alert("Please enter symbols before clicking the go button"); return false; } else return true; } function popJT(url,name){ var xwid = screen.width; xwid = xwid - 10; javaticker = window.open(url,name,'width='+xwid+',height=100,resizable=yes,scrollbars=no,toolbar=no,location=no,directories=no,status=yes,menubar=no'); javaticker.opener.name="opener"; //javaticker.moveTo(0,30); } var allow = 0; var ref = ""+location; if ((ref.indexOf("cryptocurrencieschannel.com") > 0) || (ref.indexOf("cefchannel.com") > 0) || (ref.indexOf("bdcinvestor.com") > 0) || (ref.indexOf("tickertech.com") > 0) || (ref.indexOf("xxxx:") > 0) || (ref.indexOf("javascript:") > 0) || (ref.indexOf("filseclab.com") > 0) || (ref.indexOf("msnscache.com") > 0) || (ref.indexOf("toolbar.google.com") > 0) || (ref.indexOf("etfchannel.com") > 0) || (ref.indexOf("marketnewsvideo.com") > 0) || (ref.indexOf("news.google.com") > 0) || (ref.indexOf("dividendchannel.com") > 0) || (ref.indexOf("www.google.com") > 0) || (ref.indexOf("energystockchannel.com") > 0) || (ref.indexOf("metalschannel.com") > 0) || (ref.indexOf("portfoliochannel.com") > 0) || (ref.indexOf("canadastockchannel.com") > 0) || (ref.indexOf("theonlineinvestor.com") > 0) || (ref.indexOf("investhelp.com") > 0) || (ref.indexOf("preferredstockchannel.com") > 0) || (ref.indexOf("stockoptionschannel.com") > 0) || (ref.indexOf("holdingschannel.com") > 0) || (ref.indexOf("tickertech.net") > 0) || (ref.indexOf("historicalstockprice.com") > 0) || (ref.indexOf("splithistory.com") > 0) || (ref.indexOf("stocksplithistory.com") > 0) || (ref.indexOf("google.c") > 0) || (ref.indexOf("208.71.46.190") > 0) || (ref.indexOf("search.yahoo") > 0) || (ref.indexOf("sharesoutstandinghistory.com") > 0) || (ref.indexOf("marketcaphistory.com") > 0) || (ref.indexOf("ytdreturn.com") > 0) || (ref.indexOf("averageannualreturn.com") > 0) || (ref.indexOf("redinews.com") > 0) || (ref.indexOf("technicalanalysischannel.com") > 0) || (ref.indexOf("stockdma.com") > 0) || (ref.indexOf("stockrsi.com") > 0) || (ref.indexOf("stockmacd.com") > 0) || (ref.indexOf("topdividends.com") > 0) || (ref.indexOf("monthlydividendpayingstocks.com") > 0) || (ref.indexOf("nextearningsdate.com") > 0) || (ref.indexOf("pastearnings.com") > 0) || (ref.indexOf("historicalperatio.com") > 0) || (ref.indexOf("historicalearnings.com") > 0) || (ref.indexOf("webcache.googleusercontent.com") > 0)) { allow = 1; } function ShowTTIPage() { if (allow) { document.write('\n'); } if (allow) { document.write('
\n'); } if (allow) { document.write('4/26 - 2:31 PM \; \; | \n'); } if (allow) { document.write('SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SLCA, HCP, IP, FUSN | \n'); } if (allow) { document.write('
4/26 - 1:57 PM \; \; | \n'); } if (allow) { document.write('Kuehn Law Encourages HCP, IP, SLCA, and FUSN Investors to Contact Law Firm | \n'); } if (allow) { document.write('
4/25 - 4:36 PM \; \; | \n'); } if (allow) { document.write('Fusion Pharmaceuticals Mails Circular for Special Meeting of Shareholders and Announces Receipt of Interim Order | \n'); } if (allow) { document.write('
4/23 - 1:06 PM \; \; | \n'); } if (allow) { document.write('SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CHRD, AA, FUSN, LABP | \n'); } if (allow) { document.write('
4/22 - 6:46 PM \; \; | \n'); } if (allow) { document.write('SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALPN, LABP, SWAV, FUSN | \n'); } if (allow) { document.write('
4/9 - 10:05 PM \; \; | \n'); } if (allow) { document.write('SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FUSN, LABP, JBT | \n'); } if (allow) { document.write('
4/9 - 4:06 PM \; \; | \n'); } if (allow) { document.write('Fusion Pharmaceuticals Announces Presentation of Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the AACR Annual Meeting 2024 | \n'); } if (allow) { document.write('
4/5 - 9:41 PM \; \; | \n'); } if (allow) { document.write('SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FUSN, LABP, DOMA | \n'); } if (allow) { document.write('
3/26 - 7:49 PM \; \; | \n'); } if (allow) { document.write('INVESTIGATION: The M&A Class Action Firm Announces an Investigation of Fusion Pharmaceuticals Inc. - FUSN | \n'); } if (allow) { document.write('
3/25 - 3:30 PM \; \; | \n'); } if (allow) { document.write('INVESTIGATION ALERT: Halper Sadeh LLC Investigates LABP, FUSN, KNTE | \n'); } if (allow) { document.write('
3/21 - 3:40 PM \; \; | \n'); } if (allow) { document.write('SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates FUSN, DRQ, X | \n'); } if (allow) { document.write('
3/20 - 4:46 PM \; \; | \n'); } if (allow) { document.write('SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates FUSN, DRQ, EVBG, FREE | \n'); } if (allow) { document.write('
3/20 - 4:11 PM \; \; | \n'); } if (allow) { document.write('Kuehn Law Encourages DRQ, EVBG, FREE, and FUSN Investors to Contact Law Firm | \n'); } if (allow) { document.write('
3/20 - 4:06 PM \; \; | \n'); } if (allow) { document.write('Fusion Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Clinical Program Updates | \n'); } if (allow) { document.write('
3/20 - 7:46 AM \; \; | \n'); } if (allow) { document.write('SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates FUSN, DRQ, KAMN | \n'); } if (allow) { document.write('
3/19 - 9:01 PM \; \; | \n'); } if (allow) { document.write('FUSION PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick &\; Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Fusion Pharmaceuticals Inc. - FUSN | \n'); } if (allow) { document.write('
3/19 - 3:01 AM \; \; | \n'); } if (allow) { document.write('Fusion Pharmaceuticals to be Acquired by AstraZeneca, Accelerating Development of Next-Generation Radioconjugates to Treat Cancer | \n'); } if (allow) { document.write('
3/6 - 7:46 AM \; \; | \n'); } if (allow) { document.write('Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | \n'); } if (allow) { document.write('
3/5 - 4:45 PM \; \; | \n'); } if (allow) { document.write('Fusion Pharmaceuticals to Present Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the 2024 AACR Annual Meeting | \n'); } if (allow) { document.write('
2/26 - 7:46 AM \; \; | \n'); } if (allow) { document.write('Fusion Pharmaceuticals to Present at Upcoming March Investor Conferences | \n'); } if (allow) { document.write('
more news | \n'); } if (allow) { document.write('\n'); } if (allow) { document.write(' |